Correlation Between HEMOGENYX PHARMPLC and Novo Nordisk

Can any of the company-specific risk be diversified away by investing in both HEMOGENYX PHARMPLC and Novo Nordisk at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining HEMOGENYX PHARMPLC and Novo Nordisk into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between HEMOGENYX PHARMPLC LS 01 and Novo Nordisk AS, you can compare the effects of market volatilities on HEMOGENYX PHARMPLC and Novo Nordisk and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in HEMOGENYX PHARMPLC with a short position of Novo Nordisk. Check out your portfolio center. Please also check ongoing floating volatility patterns of HEMOGENYX PHARMPLC and Novo Nordisk.

Diversification Opportunities for HEMOGENYX PHARMPLC and Novo Nordisk

0.24

Correlation Coefficient

HEMOGENYX PHARMPLC  Novo Nordisk

Modest diversification

The 3 months correlation between HEMOGENYX and Novo is 0.24. Overlapping area represents the amount of risk that can be diversified away by holding HEMOGENYX PHARMPLC LS 01 and Novo Nordisk AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novo Nordisk AS and HEMOGENYX PHARMPLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on HEMOGENYX PHARMPLC LS 01 are associated (or correlated) with Novo Nordisk. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novo Nordisk AS has no effect on the direction of HEMOGENYX PHARMPLC i.e., HEMOGENYX PHARMPLC and Novo Nordisk go up and down completely randomly.

Pair Corralation between HEMOGENYX PHARMPLC and Novo Nordisk

Assuming the 90 days horizon HEMOGENYX PHARMPLC LS 01 is expected to generate 30.61 times more return on investment than Novo Nordisk. However, HEMOGENYX PHARMPLC is 30.61 times more volatile than Novo Nordisk AS. It trades about 0.12 of its potential returns per unit of risk. Novo Nordisk AS is currently generating about -0.02 per unit of risk. If you would invest  440.00  in HEMOGENYX PHARMPLC LS 01 on September 23, 2024 and sell it today you would lose (61.00) from holding HEMOGENYX PHARMPLC LS 01 or give up 13.86% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	98.48%
Values	Daily Returns

HEMOGENYX PHARMPLC LS 01  vs.  Novo Nordisk AS

HEMOGENYX PHARMPLC

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in HEMOGENYX PHARMPLC LS 01 are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, HEMOGENYX PHARMPLC reported solid returns over the last few months and may actually be approaching a breakup point.

Novo Nordisk AS

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Novo Nordisk is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders.

Pair Trading with HEMOGENYX PHARMPLC and Novo Nordisk

The main advantage of trading using opposite HEMOGENYX PHARMPLC and Novo Nordisk positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if HEMOGENYX PHARMPLC position performs unexpectedly, Novo Nordisk can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will offset losses from the drop in Novo Nordisk's long position.

The idea behind HEMOGENYX PHARMPLC LS 01 and Novo Nordisk AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.